All In Biotech

Drug Trial Radar · NCT06211062

The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Last checked: Nov 20, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 20, 2022

Primary completion

Feb 24, 2026

Study completion Feb 24, 2026

Sponsor

Lead sponsor
Nova Southeastern UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are: * how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic/brain interface? * how well is it working on IBS severity? The study sample is 100 male and female participants aged 45 to 70 years with ME/CFS (per the Canadian Consensus Criteria); one-half of the participants will have co-morbid IBS (per Rome IV criteria). Participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).

Conditions

  • ME/CFS
  • IBS - Irritable Bowel Syndrome

Interventions

  • Floradapt Intensive GIDrug

    one capsule daily for the eight week intervention

  • PlaceboOther

    one capsule daily for the eight week intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence of Intervention-Related Adverse Events [Safety]Time frame: from baseline to the eight week visit
  2. The Measurement of Biomarker Response to an Intervention in the Blood [Efficacy]Time frame: from baseline to the eight week visit
  3. level of CRP (C-reactive protein)Time frame: from baseline to the eight week visit
  4. The pro-inflammatory cytokines level e.g. IL-1, IL-6, and TNF-αTime frame: from baseline to the eight week visit
  5. The Symptom Severity Measurement [Efficacy]Time frame: from baseline to the eight week visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute for Neuroimmune Medicine

    Fort Lauderdale, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.